GILD vs KROS
GILD: A leading biopharmaceutical innovator specializing in life-saving HIV therapies and complex CAR T-cell cancer treatments. KROS: Keros Therapeutics develops novel protein therapeutics targeting the TGF-ß pathway to address severe neuromuscular, bone, and blood disorders.
Side-by-side fundamentals
| Metric | GILD | KROS | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $147.10 | $11.64 | |
| Market cap | $182.4B | $231M | |
| Net margin FY2025, SEC XBRL | +28.9% | +35.7% | KROS higher |
| Operating margin FY2025, SEC XBRL | +34.0% | +27.7% | GILD higher |
| ROE FY2025, SEC XBRL | +37.6% | +28.7% | GILD higher |
| ROA FY2025, SEC XBRL | +14.4% | +25.7% | KROS higher |
| Debt / equity as of 2026-09-03 | 2.22 | 0.00 | KROS lower |
| Revenue growth (YoY) as of 2026-09-03 | +5.5% | -93.5% | GILD higher |
| Revenue CAGR (3y) SEC XBRL | +2.6% | n/a | |
| Dividend yield as of 2026-09-03 | +2.2% | n/a | |
| Dividend streak (yrs) SEC XBRL | 11 | 0 | GILD higher |
| Beta as of 2026-09-03 | 0.37 | 0.50 | |
| 1-year return as of 2026-10-08 close | +24.4% | -27.1% | GILD higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.